Kobayashi Pharmaceutical Co., Ltd. (TYO:4967)
Japan
· Delayed Price · Currency is JPY 5,610.00
-22.00 (-0.39%)
Mar 10, 2026, 3:30 PM JST
Kobayashi Pharmaceutical Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Cash & Equivalents | 62,314 | 50,873 | 71,536 | 96,233 | 95,024 | Upgrade
|
| Short-Term Investments | 8,300 | 14,872 | 8,300 | 8,300 | 14,022 | Upgrade
|
| Cash & Short-Term Investments | 70,614 | 65,745 | 79,836 | 104,533 | 109,046 | Upgrade
|
| Cash Growth | 7.41% | -17.65% | -23.63% | -4.14% | 15.59% | Upgrade
|
| Receivables | 52,135 | 49,384 | 52,984 | 47,853 | 55,147 | Upgrade
|
| Inventory | 22,752 | 24,163 | 22,081 | 17,678 | 15,107 | Upgrade
|
| Other Current Assets | 3,319 | 5,176 | 3,430 | 2,828 | 2,589 | Upgrade
|
| Total Current Assets | 148,820 | 144,468 | 158,331 | 172,892 | 181,889 | Upgrade
|
| Property, Plant & Equipment | 67,367 | 67,448 | 47,665 | 34,778 | 22,524 | Upgrade
|
| Long-Term Investments | 35,128 | 28,421 | 36,083 | 32,123 | 33,177 | Upgrade
|
| Goodwill | 7,711 | 9,260 | 9,655 | 7,147 | 7,189 | Upgrade
|
| Other Intangible Assets | 9,703 | 11,414 | 11,959 | 6,160 | 5,469 | Upgrade
|
| Long-Term Deferred Tax Assets | 5,264 | 3,087 | 2,647 | 1,750 | 1,489 | Upgrade
|
| Other Long-Term Assets | 2 | 1 | 1 | 2 | 1 | Upgrade
|
| Total Assets | 275,329 | 265,368 | 267,473 | 255,827 | 252,554 | Upgrade
|
| Accounts Payable | 14,898 | 14,688 | 17,305 | 18,056 | 17,444 | Upgrade
|
| Accrued Expenses | 3,052 | 2,840 | 2,705 | 2,553 | 2,486 | Upgrade
|
| Short-Term Debt | - | - | - | - | 1 | Upgrade
|
| Current Portion of Leases | 319 | 343 | 379 | 261 | 169 | Upgrade
|
| Current Income Taxes Payable | 33,906 | 19,376 | 29,884 | 25,317 | 25,662 | Upgrade
|
| Other Current Liabilities | 7,962 | 9,176 | 5,838 | 5,622 | 4,941 | Upgrade
|
| Total Current Liabilities | 60,137 | 46,423 | 56,111 | 51,809 | 50,703 | Upgrade
|
| Long-Term Leases | 359 | 503 | 608 | 531 | 460 | Upgrade
|
| Pension & Post-Retirement Benefits | 989 | 1,005 | 939 | 2,034 | 2,019 | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | 1,554 | 2,594 | 1,310 | 1,564 | Upgrade
|
| Other Long-Term Liabilities | 2,837 | 2,413 | 2,405 | 2,244 | 2,209 | Upgrade
|
| Total Liabilities | 64,322 | 51,898 | 62,657 | 57,928 | 56,955 | Upgrade
|
| Common Stock | 3,450 | 3,450 | 3,450 | 3,450 | 3,450 | Upgrade
|
| Additional Paid-In Capital | 522 | 522 | 522 | 522 | 4,183 | Upgrade
|
| Retained Earnings | 204,240 | 208,240 | 205,681 | 194,285 | 200,534 | Upgrade
|
| Treasury Stock | -24,767 | -24,767 | -24,766 | -14,482 | -23,706 | Upgrade
|
| Comprehensive Income & Other | 27,553 | 26,021 | 19,929 | 14,124 | 11,138 | Upgrade
|
| Total Common Equity | 210,998 | 213,466 | 204,816 | 197,899 | 195,599 | Upgrade
|
| Minority Interest | 9 | 4 | - | - | - | Upgrade
|
| Shareholders' Equity | 211,007 | 213,470 | 204,816 | 197,899 | 195,599 | Upgrade
|
| Total Liabilities & Equity | 275,329 | 265,368 | 267,473 | 255,827 | 252,554 | Upgrade
|
| Total Debt | 678 | 846 | 987 | 792 | 630 | Upgrade
|
| Net Cash (Debt) | 69,936 | 64,899 | 78,849 | 103,741 | 108,416 | Upgrade
|
| Net Cash Growth | 7.76% | -17.69% | -23.99% | -4.31% | 15.77% | Upgrade
|
| Net Cash Per Share | 940.77 | 873.03 | 1039.65 | 1344.98 | 1387.72 | Upgrade
|
| Filing Date Shares Outstanding | 74.34 | 74.34 | 74.34 | 76.13 | 77.28 | Upgrade
|
| Total Common Shares Outstanding | 74.34 | 74.34 | 74.34 | 76.01 | 77.74 | Upgrade
|
| Working Capital | 88,683 | 98,045 | 102,220 | 121,083 | 131,186 | Upgrade
|
| Book Value Per Share | 2838.33 | 2871.53 | 2755.17 | 2603.46 | 2516.20 | Upgrade
|
| Tangible Book Value | 193,584 | 192,792 | 183,202 | 184,592 | 182,941 | Upgrade
|
| Tangible Book Value Per Share | 2604.08 | 2593.42 | 2464.42 | 2428.40 | 2353.37 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.